The European Society of Medical Oncology (ESMO) clinical practice guidelines  are intended to provide oncology professionals with a set of recommendations for the best standards of cancer care, based on the findings of evidence-based medicine. The ESMO guidelines are also endorsed by the Japanese Society of Medical Oncology (JSMO) and include the following recommendations for the use of sFLC measurements:
sFLC analysis should be used in the initial diagnostic work-up of MM.
Response evaluation and follow-up
IMWG response criteria, which include sFLC analysis, should be used for response evaluation (Section 25.3.5). Outside the context of a clinical trial, it is recommended that serum and urine electrophoresis and/or sFLC determination should be carried out every 2 - 3 months.